Adding abiraterone acetate plus prednisolone to standard therapy lengthens survival in non-metastatic high-risk prostate cancer

Share :
Published: 23 Sep 2021
Views: 965
Prof Nick James - The Institute of Cancer Research, London, UK

Prof Nick James speaks to ecancer about the combined analysis from two comparisons in the STAMPEDE platform protocol.

This study compared abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) to ADT alone for men with high-risk nonmetastatic (M0) prostate cancer (PCa). Initially, he explains the rationale and design of this study. Prof James then discusses the results of this study. He mentions that two years of AAP-based therapy significantly improves metastasis-free survival & survival of high-risk M0 PCa starting ADT and should be considered a new standard of care.

Prof James concludes by discussing what the future holds for the STAMPEDE trial.